Satellos Bioscience Inc. Common Stock MSLE

Satellos Bioscience Inc is a Canadian biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation, which Satellos has identified as a root cause of the progressive nature of this disease.

• GlobeNewswire Inc. 24 sept

  Satellos Announces FDA Clearance of IND Application for Forazapadin in Facioscapulohumeral Muscular Dystrophy (FSHD) and a Partnership with FSHD Canada Foundation Providing Non-Dilutive Financing to Support Clinical Development

  Satellos Bioscience received FDA clearance for its IND application to test forazapadin in facioscapulohumeral muscular dystrophy (FSHD), expanding the drug candidate into a second degenerative muscle disease. The FSHD Canada Foundation will provide up to US$5 million in non-dilutive financing to support clinical development, with a Phase 2 study expected to begin in Q4 2026. Forazapadin is an AAK1 inhibitor designed to restore muscle repair and regeneration.

  

• GlobeNewswire Inc. 17 jun

  Satellos Bioscience Announces Results of Annual Meeting of Shareholders

  Satellos Bioscience Inc. held its Annual Meeting of Shareholders on June 17, 2026, with 55.3% shareholder participation. All nine director nominees were elected with strong support, with most receiving over 99% approval votes. PricewaterhouseCoopers LLP was re-appointed as the company's auditor. The clinical-stage biotech company continues advancing SAT-3247, its lead candidate for treating degenerative muscle diseases including DMD, with Phase II trials (BASECAMP in pediatrics and TRAILHEAD in adults) progressing on schedule.